Europital launches as a science-driven full-service CRO

Expanded CRO services to support biotechs and mid-sized pharma companies across trials in more than 40 countries.

The expanded clinical research offering will see Europital support clients in more than 40 countries from investigational new drug (IND) through to commercial launch.

Dr Mohamed El Malt, Chief Medical Officer of Europita, said: “It’s no secret, there is a large gap in the CRO industry for these small innovators; what they need is a science-driven CRO that will support them closely with an experienced senior team but combined with a global trial network."

Europital has regional offices in Belgium, Hungary and the UK, with customers based in Europe and the US. Innovators developing therapies for oncology, infectious diseases, inflammatory and autoimmune diseases will be the major beneficiaries of the company's multifunctional and operational capabilities.

Sponsors who will particularly benefit are those that require a full range of CRO services for complex molecules and trial designs that necessitate senior medical and scientific oversight.

In addition to its regional offices in Europe, Europital has built a global network of trusted partners during the last 10 years with local operational expertise and preferential supply trial site agreements in the US, Canada, Russia, India, the Middle East and North Africa and Australia.

Dr El Malt explained that the decision to launch as a full-service CRO reflects the many requests it received from its clients to work on additional aspects of their clinical trials, the services for which they did not have in-house. Now, with the expansion, the company can provide a 360-degree CRO service to innovators in the pharmaceutical, biotechnology and medical devices sectors.